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Available online 12 December 2015Skin ﬁbroblasts were obtained from a 57-year-oldwoman diagnosedwith frontotemporal dementia. The disease
is caused by a P301L mutation in microtubule-associated protein tau (MAPT). Induced pluripotent stem cells
(iPSCs) were established by electroporation with episomal plasmids containing hOCT4, hSOX2, hKLF2, hL-MYC,
hLIN-28 and shP53. iPSCs were free of genomically integrated reprogramming genes, contained the expected
c.902CNT substitution in exon 10 of the MAPT gene, expressed the expected pluripotency markers, displayed
in vitro differentiation potential to the three germ layers and had normal karyotype. The iPSC line may be useful
for studying hereditary frontotemporal dementia and TAU pathology in vitro.
© 2015 Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Resource tableName of stem cell construct H251 C3stitution Bioneer A/S
erson who created resource Mikkel Aabech Rasmussen, Bjørn Holst
ontact person and email Bjørn Holst, bho@bioneer.dk
ate archived/stock date July 1, 2012
rigin Human skin ﬁbroblasts
ype of resource Biological reagent: induced pluripotent stem
cell (iPS); derived from a MAPT P301L
mutation carrierub-type Induced pluripotent stem cell
ey transcription factors Episomal plasmids containing hOCT4, hSOX2,
hL-MYC, hKLF4, hLIN28 and shP53 (Addgene
plasmids 27077, 27078 and 27080;
Okita et al. 2011)uthentication Identity and purity of cell line conﬁrmed by
integration analysis, sequencing of mutation,
pluripotency analysis, karyotyping and
in vitro differentiation (Figure 1).nk to related literature (direct
URL links and full references)http://brain.oxfordjournals.org/content/
138/11/3345.longformation in public databases Link to any data or information about this
resource in a database if applicableicle under the CC BY-NC-ND licenseResource detailsFibroblasts were obtained from a 57-year old woman diagnosed
with frontotemporal dementia and heterozygous for a P301L mutation
in microtubule-associated protein tau (MAPT). iPSC-derived neurons
from a patient with a P301L mutation were recently shown to undergo
faster maturation and display altered mitochondrial transport and
contorted processes compared with controls (Iovino et al. 2015).
Reprogrammingwas performed by electroporationwith three episomal
plasmids containing hOCT4 with or without a short hairpin to TP53
(shp53), hSOX2 and hKLF4, and hL-MYC and hLIN28 (Okita et al. 2011).
This method had previously been used to establish integration-free
iPSC from an 18-year old healthy male (Rasmussen et al. 2014). Four
weeks after reprogramming, an average of 20 colonies per 1 × 105 ﬁbro-
blasts (0.02%) emerged with the inclusion of shp53, whereas, no colo-
nies were observed without shp53. Integration analysis with plasmid-
speciﬁc primers showed that hOCT4, hSOX2 and hLIN28, present on
each of the three plasmids, had not integrated into the genome
(Fig. 1A) and sequencing conﬁrmed the presence of a c.902CNT substi-
tution in one of the alleles of exon 10 in theMAPT gene corresponding to
a P301L mutation (Fig. 1B). Pluripotency analysis showed that tran-
scription from the endogenous pluripotency genes NANOG, POU5F1
(OCT4), TDGF1, DNMT3B, GABRB3 and GDF3 were between 100 and
10,000 times upregulated compared with ﬁbroblasts (Fig. 1C) and(http://creativecommons.org/licenses/by-nc-nd/4.0/).
71M.A. Rasmussen et al. / Stem Cell Research 16 (2016) 70–74immunocytochemical (ICC) analysis demonstrated the presence of
the pluripotency markers OCT4, NANOG, TRA1-60, TRA1-81,
SSEA3 and SSEA4 at the protein level (Fig. 1D). Finally, in vitro dif-
ferentiation followed by ICC analysis with the mesodermal marker
smooth muscle actin (SMA), the endodermal marker alpha-feto
protein (AFP) and the ectodermal marker beta-III-Tubulin (TUJI)
demonstrated the differentiation potential into all three germ
layers (Fig. 1E).Materials and methods
Unless otherwise stated, consumables and reagents were purchased
from Sigma-Aldrich, St. Louis, MO, USA.Fig. 1. A. Integration analysis. Quantitative PCR (qPCR) on genomic DNA from H251 C3 induce
episomal plasmids (positive control) with plasmid-speciﬁc primers of hOCT4, hSOX2, and hLIN
B. Sequencing of mutation. Sequencing of exon 13 of theMAPT gene in H251 C3 induced plur
red arrow. C. Pluripotency expression analysis. Quantitative reverse-transcriptase PCR (qRT-PC
broblasts and the iPSC line BIONi010-A (Rasmussen et al. 2014) as a positive control with th
GDF3. Relative expression is shown as the fold change (2−ΔΔCt) with GAPDH and ﬁbroblasts as
induced pluripotent stem cells with the pluripotency markers OCT3/4, TRA1-81, NANOG, TRA1
nocytochemical staining of plated embryoid bodies (EBs) from H251 C3 induced pluripoten
betaIIItubulin (TUJI). Scale bars correspond to 100 μm. F. Karyotyping. Representative karyotypEstablishment of iPSC
A skin biopsy was obtained from a 57-year old woman carrying a
P301Lmutation inMAPT. The studywas approved by the regional scien-
tiﬁc ethical committee in the Capital Region of Denmark (RH), andwrit-
ten informed consent was obtained from the donor. Fibroblasts were
cultured in ﬁbroblast medium, consisting of Dulbecco's Modiﬁed Eagle
Medium (DMEM) supplemented with 10% fetal bovine serum (FBS),
2 mM L-glutamine and 1% penicillin and streptomycin (Pen/Strep).
1 × 105 ﬁbroblasts were electroporated with a total of 1 μg of episomal
plasmids containing hOCT4 with or without a short hairpin to TP53
(shp53; Addgene plasmids 27077 and 27076, respectively), hSOX2 and
hKLF4 (Addgene plasmid 27078), and hL-MYC and hLIN28 (Addgene
plasmid 27,080; Okita et al. 2011) and cultured in ﬁbroblast medium.d pluripotent stem cells (iPSCs), ﬁbroblasts and a pool of ﬁbroblasts electroporated with
28. Data is shown as the fold change (2−ΔΔCt) with GAPDH and ﬁbroblasts as references.
ipotent stem cells showing a c.1216CNT substitution in one of the alleles marked with a
R) expression analyses on cDNA from H251 C3 induced pluripotent stem cells (iPSCs), ﬁ-
e endogenous pluripotency genes NANOG, POU5F1 (OCT4), TDGF1, DNMT3B, GABRB3 and
references. D. Immunoﬂuorescence staining. Immunocytochemical detection of H251 C3
-60, SSEA3, and SSEA4. Scale bars correspond to 400 μm. E. In vitro differentiation. Immu-
t stem cells on day 28 with smooth muscle actin (SMA), alpha-fetoprotein (AFP) and
e of H251 C3 induced pluripotent stem cells.
Fig. 1 (continued).
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Fig. 1 (continued).
73M.A. Rasmussen et al. / Stem Cell Research 16 (2016) 70–74Electroporation was carried out using a Neon™ electroporation device
with two pulses at 1200 V for 20 ms (Life Technologies, Carlsbad, CA,
USA). One week after electroporation, the ﬁbroblasts were trypsinized
and split 1:2 onto hESC-qualiﬁed Matrigel-coated dishes (BD Biosci-
ences, Franklin Lakes, NJ, USA) and cultured in mTeSR1 medium
(Stem Cell Technologies, Vancouver, BC, Canada) in 5% O2, 5% CO2 in
N2. After four weeks, primary iPSC colonies were dissected out manual-
ly, transferred to new Matrigel-coated dishes, and cultured in mTeSR1.
The iPSC lines were split 1:6 every 5–6 days with Dispase (Stem Cell
Technologies, Vancouver, BC, Canada). At passage 10, the iPSC lines
were harvested for subsequent analyses or frozen in liquid nitrogen in
mTeSR1 containing 10% DMSO.
Integration analysis
DNA was puriﬁed from iPSCs, ﬁbroblasts and a pool of ﬁbroblasts
electroporated with episomal plasmids as a positive control using the
DNeasy Blood and Tissue kit (Qiagen, Hilden, Germany). qPCR analysis
was carried out with the primers OCT4-pla, SOX2-pla and LIN-28-pla,
which are speciﬁc to the three plasmids (Okita et al. 2011) and data
was analyzed using the 2−ΔΔCt method relative to GAPDH with ﬁbro-
blasts as a reference (set to 1).
Pluripotency expression analysis.
Total RNA was puriﬁed from iPSCs, ﬁbroblasts and the iPSC line
BIONi010-A (Rasmussen et al. 2014) as a positive control using RNeasy
mini kit (Qiagen, Hilden, Germany). Conversion to cDNAwas performed
with RevertAid First Strand cDNA synthesis kit (Thermo Scientiﬁc,Wal-
tham, MA, USA). qPCR analysis was carried out using the TaqMan
primers GAPDH Hs03929097_g1, NANOG Hs02387400_g1, POU5F1
Hs00999632_g1, TDGF1 Hs02339497_g1, DMNT3B Hs00171876_m1,
GABRB3 Hs00241459_m1 and GDF3 Hs00220998_m1 (Thermo Scientiﬁc,
Waltham, MA, USA; International Stem Cell Banking Initiative). Data
was analyzed using the 2-ΔΔCt method relative to GAPDH with ﬁbro-
blasts as a reference (set to 1).Sequencing of mutation
Sanger sequencing of exon 10 of theMAPT genewas carried out in an
ABI PRISM 310 Genetic Analyzer using the primers MAPT_Ex10Fw
tcactcatcgaaagtggagg and MAPT_Ex10Rv cagtgtctcgcaagtgtacg
(NM_001123066.3).
Immunoﬂuorescence staining
iPSCs were ﬁxed with 4% paraformaldehyde (PFA) in PBS for 15min
and stained by standard immunoﬂuorescence procedures. The primary
antibodies (Table 1) were visualized with the secondary antibodies
Alexa 488 or Alexa 594 diluted 1:400 (Life technologies, Carlsbad, CA,
USA) and counterstained with Hoechst bisbenzimide 33258. Images
were acquired on a Leica DMRB-ﬂuorescence microscope (Leica
Microsystems, Wetzlar, Germany).
In vitro differentiation
Embryoid body (EB) formation was performed by transferring
Dispase-treated clumps of iPSC to ultra-low attachment plates (Corning,
Corning, NY, USA) in mTeSR1. After 2 days of culture, the medium was
changed to DMEM/F12 containing 20% knockout serum replacement
(Life Technologies, Carlsbad, CA, USA), 1× non-essential amino acid,
2 mM L-glutamine, 0.1 mM 2-mercaptoethanol and 1% pen/strep.
After 7 days, the EBs were plated on 0.1% gelatin-coated culture dishes
and cultured in DMEM supplemented with 10% FBS, 2 mM L-glutamine
and 1% pen/strep for up to three weeks. The cells were ﬁxed for 15 min
in 4% PFA for ICC analyses with the antibodies TUJI, SMA and AFP
(Table 1).
Karyotyping
iPSCs and ﬁbroblasts were treated for 45 min with KaryoMAX
colcemid (Life Technologies, Carlsbad, CA, USA) and harvested in fresh
ﬁxative containing 25% acetic acid and 75% methanol. Karyotyping
Table 1
Antibodies used for immunocytochemistry.
Antibody and host species Dilution Company and catalog
number
Pluripotency Rabbit anti-NANOG 1:500 Peprotech, 500-P236
Goat anti-OCT4 1:500 Santa Cruz, sc-8628
Rat anti-SSEA3 1:100 Biolegend, 330,302
Mouse anti-SSEA4 1:100 Biolegend, 330,402
Mouse anti-Tra-1-81 1:200 Biolegend, 330,702
Mouse anti-Tra-1-60 1:200 Biolegend, 330,602
In vitro
differentiation
mouse anti-Smooth
muscle actin (sma)
Rabbit anti-Alpha-1-
fetoprotein (AFP)
1:500
1:500
DAKO, M0851
DAKO, A0008
Mouse anti-Beta-III-
tubulin (TUJI)
1:4000 Sigma-Aldrich, T8660
74 M.A. Rasmussen et al. / Stem Cell Research 16 (2016) 70–74was performed on G-banded metaphase chromosomes using standard
cytogenetic procedures.
Veriﬁcation and authentication
Karyotyping was performed at the Center for Applied Human
Molecular Genetics, Kennedy Center, Glostrup, Denmark. At least 10
metaphases were analysed per sample with an approximate resolution
of 550 to 600 bands per haploid genome. The results showed a normal
46, XX karyotype, free of any discernible abnormalities (Fig. 1F). iPSC
line identity and purity was conﬁrmed by sequencing of the MAPT
gene (Fig. 1B) and ICC with pluripotency markers (Fig. 1D).Acknowledgments
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